drugset / Trial / NCT00080275

Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)

NCT00080275

Phase 3 Completed 600 enrolled Kos Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this 24 week study is to compare the effectiveness and safety of different doses of Niacin ER/Simvastatin (NS) in subjects with elevated fat levels in their blood (dyslipidemia). At least 600 subjects with a similar medical condition will take part in this study.

Timeline

Start
2004-03
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Niacin Small molecule 2000 mg
Subject Simvastatin Small molecule 40 mg

Indications